Nylexa (cysteamine IV) / NovaBiotics - LARVOL DELTA

Educational Resource Review: Nylexa animation. (PubMed, JAC Antimicrob Resist) - No abstract available

Journal • Review

NovaBiotics Announces Cysteamine Bitartrate (NM002) Included in REMAP-CAP Phase 3 Clinical Trial for Community Acquired Pneumonia (PRNewswire) - "NovaBiotics Ltd...announces that the Company's proprietary intravenous (IV) cysteamine bitartrate (NM002) therapy candidate is included in a global Phase 3 clinical trial being conducted and funded as part of REMAP-CAP (Randomised, Embedded, Multi-factorial, Adaptive Platform Trial for Community Acquired Pneumonia)....NovaBiotics has provided NM002 doses for the initial UK phase of REMAP-CAP and has developed a scalable manufacturing process for NM002 to supply the balance of the trial."

Trial status • Infectious Disease • Novel Coronavirus Disease